Call Options

9 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.42 - $8.83 $7,062 - $9,713
-1,100 Reduced 10.48%
9,400 $78,000
Q2 2024

Aug 14, 2024

BUY
$5.36 - $7.11 $54,672 - $72,522
10,200 Added 3400.0%
10,500 $66,000
Q1 2024

May 15, 2024

SELL
$5.24 - $6.34 $33,012 - $39,942
-6,300 Reduced 95.45%
300 $1,000
Q4 2023

Feb 14, 2024

SELL
$3.36 - $6.21 $5,712 - $10,557
-1,700 Reduced 20.48%
6,600 $40,000
Q3 2023

Nov 14, 2023

BUY
$2.76 - $4.59 $6,623 - $11,016
2,400 Added 40.68%
8,300 $35,000
Q2 2023

Aug 14, 2023

SELL
$1.33 - $3.1 $19,551 - $45,570
-14,700 Reduced 71.36%
5,900 $18,000
Q1 2023

May 15, 2023

SELL
$1.27 - $2.7 $1,397 - $2,970
-1,100 Reduced 5.07%
20,600 $28,000
Q4 2022

Feb 14, 2023

SELL
$1.96 - $2.61 $67,620 - $90,045
-34,500 Reduced 61.39%
21,700 $43,000
Q3 2022

Nov 14, 2022

SELL
$2.02 - $3.62 $4,444 - $7,964
-2,200 Reduced 3.77%
56,200 $114,000

Others Institutions Holding AMRX

About Amneal Pharmaceuticals, Inc.


  • Ticker AMRX
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 151,408,992
  • Market Cap $1.18B
  • Description
  • Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment develops, manufactures, and comme...
More about AMRX
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.